PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.02
D/E ratio near Healthcare median of 0.02. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
3.80
Dangerously high net debt exceeding 1.5x Healthcare median of 1.31. Michael Burry would check for debt covenant compliance and refinancing risks.
-2327.49
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.50
Current ratio 50-75% of Healthcare median of 2.03. Martin Whitman would look for hidden assets or working capital optimization.
No Data
No Data available this quarter, please select a different quarter.